Prasad ML, Osborne MP, Giri DD, Hoda SA (2000) Microinvasive carcinoma (T1mic) of the breast: clinicopathologic profile of 21 cases. Am J Surg Pathol 24(3):422–428. https://doi.org/10.1097/00000478-200003000-00012

Article  CAS  PubMed  Google Scholar 

Shatat L, Gloyeske N, Madan R, O’Neil M, Tawfik O, Fan F (2013) Microinvasive breast carcinoma carries an excellent prognosis regardless of the tumor characteristics. Hum Pathol 44(12):2684–2689. https://doi.org/10.1016/j.humpath.2013.07.010

Article  PubMed  Google Scholar 

Costarelli L, Cianchetti E, Corsi F, Friedman D, Ghilli M, Lacaria M, Menghini L, Murgo R, Ponti A, Rinaldi S, Del Turco MR, Taffurelli M, Tinterri C, Tomatis M, Fortunato L (2019) Microinvasive breast carcinoma: an analysis from ten Senonetwork Italia breast centres. Eur J Surg Oncol 45(2):147–152. https://doi.org/10.1016/j.ejso.2018.09.024

Article  PubMed  Google Scholar 

Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ, Hortobagyi GN (2017) Breast cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67(4):290–303. https://doi.org/10.3322/caac.21393

Article  PubMed  Google Scholar 

Kim M, Kim HJ, Chung YR, Kang E, Kim EK, Kim SH, Kim YJ, Kim JH, Kim IA, Park SY (2018) Microinvasive carcinoma versus ductal carcinoma in situ: a comparison of clinicopathological features and clinical outcomes. J Breast Cancer 21(2):197–205. https://doi.org/10.4048/jbc.2018.21.2.197

Article  PubMed  PubMed Central  Google Scholar 

Xu H, Han Y, Wu Y, Wang Y, Wang J, Xu B (2022) Clinicopathological characteristics and prognosis of microinvasive breast cancer: A population-based analysis. Cancer Med 11(23):4501–4512. https://doi.org/10.1002/cam4.4839

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang H, Moisini I, Turner BM, Wang X, Dhakal A, Yang Q, Kovar S, Schiffhauer LM, Hicks DG (2021) Significance of HER2 in microinvasive breast carcinoma. Am J Clin Pathol 156(1):155–165. https://doi.org/10.1093/ajcp/aqaa222

Article  CAS  PubMed  Google Scholar 

Wang L, Zhang W, Lyu S, Liu X, Zhang T, Liu S, Qin Y, Tian X, Niu Y (2015) Clinicopathologic characteristics and molecular subtypes of microinvasive carcinoma of the breast. Tumour Biol 36(4):2241–2248. https://doi.org/10.1007/s13277-014-2652-z

Article  CAS  PubMed  Google Scholar 

Shaaban AM, Hilton B, Clements K, Dodwell D, Sharma N, Kirwan C, Sawyer E, Maxwell A, Wallis M, Stobart H, Mylvaganam S, Litherland J, Brace-McDonnell S, Dulson-Cox J, Kearins O, Provenzano E, Ellis IO, Pinder SE, Thompson AM (2022) The presentation, management and outcome of patients with ductal carcinoma in situ (DCIS) with microinvasion (invasion ≤1 mm in size)-results from the UK Sloane Project. Br J Cancer 127(12):2125–2132. https://doi.org/10.1038/s41416-022-01983-4

Article  PubMed  PubMed Central  Google Scholar 

Sopik V, Sun P, Narod SA (2018) Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ. Breast Cancer Res Treat 167(3):787–795. https://doi.org/10.1007/s10549-017-4572-2

Article  PubMed  Google Scholar 

Hennigs A, Riedel F, Gondos A, Sinn P, Schirmacher P, Marmé F, Jäger D, Kauczor HU, Stieber A, Lindel K, Debus J, Golatta M, Schütz F, Sohn C, Heil J, Schneeweiss A (2016) Prognosis of breast cancer molecular subtypes in routine clinical care: a large prospective cohort study. BMC Cancer 16(1):734. https://doi.org/10.1186/s12885-016-2766-313

Article  PubMed  PubMed Central  Google Scholar 

Petrelli F, Barni S (2012) Role of HER2-neu as a prognostic factor for survival and relapse in pT1a-bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis. Med Oncol 29(4):2586–2593. https://doi.org/10.1007/s12032-012-0201-4

Article  CAS  PubMed  Google Scholar 

Cho SY, Park SY, Bae YK, Kim JY, Kim EK, Kim WG, Kwon Y, Lee A, Lee HJ, Lee JS, Park JY, Gong G, Yoon HK (2021) Standardized pathology report for breast cancer. J Breast Cancer 24(1):1–21. https://doi.org/10.4048/jbc.2021.24.e5

Article  PubMed  PubMed Central  Google Scholar 

Akrida I, Mulita F (2022) The clinical significance of HER2 expression in DCIS. Med Oncol 40(1):16. https://doi.org/10.1007/s12032-022-01876-9

Article  CAS  PubMed  Google Scholar 

Lyons JM 3rd, Stempel M, Van Zee KJ, Cody HS 3rd (2012) Axillary node staging for microinvasive breast cancer: is it justified? Ann Surg Oncol 19(11):3416–3421. https://doi.org/10.1245/s10434-012-2376-5

Article  PubMed  Google Scholar 

Pu T, Zhong X, Deng L, Li S, Qiu Y, Liu Y, Zheng H, Ye F, Bu H (2018) Long term prognosis of ductal carcinoma in situ with microinvasion: a retrospective cohort study. Int J Clin Exp Pathol 11(5):2665–2674

PubMed  PubMed Central  Google Scholar 

Fang Y, Wu J, Wang W, Fei X, Zong Y, Chen X, Huang O, He J, Chen W, Li Y, Shen K, Zhu L (2016) Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion. Oncotarget 7(39):64182–64190. https://doi.org/10.18632/oncotarget.11639

Article  PubMed  PubMed Central  Google Scholar 

Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, Schneider BP, Shen F, Fuhrman K, Baltay M, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA et al (2019) Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 37(22):1868–1875. https://doi.org/10.1200/JCO.19.00066

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns J, Kumar R (2022) Breast cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Network 20(6):691–722

Article  Google Scholar 

Cobleigh MA, Anderson SJ, Siziopikou KP, Arthur DW, Rabinovitch R, Julian TB, Parda DS, Seaward SA, Carter DL, Lyons JA, Dillmon MS, Magrinat GC, Kavadi VS, Zibelli AM, Tiriveedhi L, Hill ML, Melnik MK, Beriwal S, Mamounas EP, Wolmark N (2021) Comparison of radiation with or without concurrent trastuzumab for HER2-positive ductal carcinoma in situ resected by lumpectomy: a phase III clinical trial. J Clin Oncol 39(21):2367–2374. https://doi.org/10.1200/JCO.20.02824

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thorat MA, Levey PM, Jones JL, Pinder SE, Bundred NJ, Fentiman IS, Cuzick J (2021) Prognostic and predictive value of HER2 expression in ductal carcinoma in situ: results from the UK/ANZ DCIS randomized trial. Clin Cancer Res 27(19):5317–5324. https://doi.org/10.1158/1078-0432.CCR-21-1239

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li C, Yang Y, Wang J, Jin K, Yang Z, Yu X, Guo X, Chen X (2021) Characteristics, prognosis, risk factors, and management of recently diagnosed ductal carcinoma in situ with microinvasion. Cancer Med 10(20):7203–7212. https://doi.org/10.1002/cam4.4263

Article  PubMed  PubMed Central  Google Scholar 

Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z (2003) Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther 2(11):1113–1120

CAS  PubMed  Google Scholar